PHARMACEUTICAL COMPOSITION FOR PREVENTING AND/OR TREATING DISEASE CAUSED BY CORONAVIRUS AND/OR ROTAVIRUS

Abstract

The present invention provides a pharmaceutical composition for prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus. The pharmaceutical composition includes the following components by weight percent: 0.5-100% of taurine, 0-85% of a vitamin complex, and 0-15% of a flavoring agent.

Claims

1. A pharmaceutical composition for prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, characterized in that, it comprises following components by weight percent: 0.5-100% of taurine, 0-85% of a vitamin complex, and 0-15% of a flavoring agent.

2. The pharmaceutical composition according to claim 1, wherein it comprises the following components by weight percent: 5-100% of taurine, 0-85% of the vitamin complex, and 0-10% of the flavoring agent.

3. The pharmaceutical composition according to claim 1, wherein it comprises the following components by weight percent: 60-90% of taurine, 5-10% of the vitamin complex, and 1-5% of the flavoring agent.

4. The pharmaceutical composition according to claim 1, wherein it comprises the following components by weight percent: 85% of taurine, 10% of the vitamin complex, and 5% of the flavoring agent.

5. The pharmaceutical composition according to claim 1, wherein the disease induced by viruses of the genus coronavirus and/or the genus rotavirus is porcine viral diarrhea.

6. The pharmaceutical composition according to claim 5, wherein the porcine viral diarrhea is the diarrhea induced by a porcine epidemic diarrhea virus, a porcine transmissible gastroenteritis virus and/or a porcine rotavirus.

7. The pharmaceutical composition according to claim 1, wherein the vitamin complex is partially replaceable by a filler, the filler being one or more of starch, sucrose, glucose and lactose.

8. The pharmaceutical composition according to claim 1, wherein the vitamin complex is one or more of vitamin A, vitamin B family, vitamin C, vitamin D.sub.3, 25-hydroxyl-vitamin D.sub.3, vitamin E, vitamin K.sub.3, biotin, niacin, niacinamide, pantothenic acid, calcium pantothenate, folic acid and inose.

9. The pharmaceutical composition according to claim 14, wherein the flavoring agent is one or more of an edible aroma agent, a sweetener and a spicy flavoring agent.

10. The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is compounded with a corresponding adjuvant agent to prepare a clinically-acceptable dosage form.

11. The pharmaceutical composition according to claim 2, wherein the disease induced by viruses of the genus coronavirus and/or the genus rotavirus is the porcine viral diarrhea.

12. The pharmaceutical composition according to claim 3, wherein the disease induced by viruses of the genus coronavirus and/or the genus rotavirus is the porcine viral diarrhea.

13. The pharmaceutical composition according to claim 4, wherein the disease induced by viruses of the genus coronavirus and/or the genus rotavirus is the porcine viral diarrhea.

14. The pharmaceutical composition according to claim 11, wherein the porcine viral diarrhea is the diarrhea induced by the porcine epidemic diarrhea virus, the porcine transmissible gastroenteritis virus and/or the porcine rotavirus.

15. The pharmaceutical composition according to claim 12, wherein the porcine viral diarrhea is the diarrhea induced by the porcine epidemic diarrhea virus, the porcine transmissible gastroenteritis virus and/or the porcine rotavirus.

16. The pharmaceutical composition according to claim 13, wherein the porcine viral diarrhea is the diarrhea induced by the porcine epidemic diarrhea virus, the porcine transmissible gastroenteritis virus and/or the porcine rotavirus.

17. The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is compounded with the corresponding adjuvant agent to prepare the clinically-acceptable dosage form.

18. The pharmaceutical composition according to claim 3, wherein the pharmaceutical composition is compounded with the corresponding adjuvant agent to prepare the clinically-acceptable dosage form.

19. The pharmaceutical composition according to claim 4, wherein the pharmaceutical composition is compounded with the corresponding adjuvant agent to prepare the clinically-acceptable dosage form.

Description

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

[0025] The present invention will be further described in detail by specific embodiments. Unless otherwise specified, experiment methods hereinafter are all conventional methods in the art. Unless otherwise specified, the used ingredients or materials are all ingredients or materials that are commercially available. The described below are preferred implementations of the present invention. It should be noted that for those ordinarily skilled in the art, some improvements may be made without departing from the principles of the present invention and such improvements shall be deemed as falling within the protection scope of the present invention.

Embodiment 1 Use of Taurine in Prevention of Porcine Epidemic Diarrhea of Newborn Piglets

[0026] Prevention of the porcine epidemic diarrhea on the newborn piglets with taurine was implemented by orally administering taurine to pregnant sows.

[0027] Drug Administration Time:

[0028] 3-30 days before birth of piglets until 15 days after birth of piglets. In consideration of a use-cost, the drug administration time is preferably 5-20 days before birth of piglets until 10 days after birth of piglets, and more preferably 7-14 days before birth of piglets until 5 days after birth of piglets. The effect is subject to an obvious time-effect relationship. The drug administration time for before birth of piglets directly determines a disease incidence of the newborn piglets.

[0029] Drug Administration Dosage:

[0030] each pregnant sow was administered with 5-500 g of taurine per day, and the administration was in a single dose or in divided doses. The effect is subject to an obvious quantity-effect relationship.

[0031] Specific Operations:

[0032] pregnant sows were selected and excrement thereof was detected by RT-PCR to determine the pregnant sows carrying PEDV in vivo. 60 PEDV-carried pregnant sows were divided into two groups randomly. Control group: conventional feeding; experimental group: conventional feeding+50 g per sow per day of taurine. Prevention results of the two groups are listed in Table 1. As seen from Table 1, the disease incidence and a death rate of the experimental group which was administered with taurine are obviously decreased compared to those of the control group (P<0.01).

TABLE-US-00001 TABLE 1 Disease incidence Death rate of of the new the newborn Group Dosage of taurine born piglets (%) piglets (%) Control group 0 100%  96.6% Experimental 50 g per sow per day 85% 75.1% group

Embodiment 2 Use of Taurine in Treatment of the Porcine Epidemic Diarrhea of Newborn Piglets

[0033] Treatment of the porcine epidemic diarrhea on newborn piglets with taurine was implemented by orally administering a taurine solution to diseased suckling piglets and administering taurine to lactating sows, that is, simultaneous treatment of both the suckling piglets and the lactating sows.

[0034] Drug Administration Time:

[0035] the administration by drenching/mixed-feeding was carried out on the day when the disease occurred in the suckling piglets, and a non-interrupted administration lasted for 3-10 days. Lactating sows: non-interrupted oral administration lasted for 5-10 days.

[0036] Drug Administration Dosage:

[0037] the administration by drenching or mixed-feeding was carried out on the day when the disease occurred in the suckling piglets. The administration by drenching: 2% taurine solution at a dosage of 1-5 mL per time and it was taken 2-6 times per day. The administration by mixed-feeding: 1-20 g/L of taurine solution was drunk freely. Lactating sows: each sow was administered with 5-500 g of taurine per day and the administration was in a single dose or in divided doses.

[0038] Specific Operations:

[0039] 40 litters of diseased newborn suckling piglets and sows thereof were selected and randomly divided into two groups equivalently. Control group: conventional supportive therapy (fluid infusion+antibiotic therapy+atropine sulfate); experimental group: treatment with taurine. Treatment results of the two groups are listed in Table 2. As seen from Table 2, a 10-day-aged survival rate and a weaned survival rate of the piglets in the experimental group are both significantly improved compared to those of the control group (P<0.05), and prognosis of the piglets is good.

TABLE-US-00002 TABLE 2 Dosage of Dosage of 10-day-aged taurine for the taurine for the survival rate Weaned Group lactating sows piglets (%) survival rate Prognosis Control group 0 0 8.3 3.2 Poor Experimental 100 g per sow 0.2 g per piglet 22.5 20.7 Good group per day per day

Embodiment 3 Use of Taurine in Prevention of the Porcine Epidemic Diarrhea of Weaned Piglets, Care Pigs and Finishing Pigs

[0040] Prevention of the porcine epidemic diarrhea on the weaned piglets, the care pigs and the finishing pigs with taurine was implemented by orally administering taurine to a swine herd, wherein the administration may be carried out by means of feeding in water or mixed feeding.

[0041] Drug Administration Time:

[0042] a preventative administration was carried out during an epidemic period of the disease, or in autumn, winter and spring when the temperature was low and changed greatly, that is, in the season when the porcine epidemic diarrhea frequently occurs. Generally, the administration can be carried out for a long-term. In consideration of the use-cost, the drug administration time is preferably 3-30 days, and more preferably, 7-14 days. The effect is subject to an obvious time-effect relationship.

[0043] Drug Administration Dosage:

[0044] 0.005-2% by weight of taurine was added in daily-drinking water for the pigs to drink freely; or taurine accounting for 0.01-5% by weight of the feed was added thereto, which is equivalent to a dosage of 50-10000 mg per kilogram of body weight per day of taurine, and the administration was in a single dose or in divided doses. The effect is subject to an obvious quantity-effect relationship.

[0045] Specific Operations:

[0046] 120 healthy weaned piglets, 120 healthy care pigs and 120 healthy finishing pigs were selected and randomly divided into two groups equivalently. Control group: conventional feeding; experimental group: conventional feeding+taurine (the dosage of taurine was 200 mg per kilogram of body weight per day). The prevention results of the two groups are listed in Table 3. As seen from Table 3, the disease incidence of the experimental group is lowered compared to that of the control group (P<0.05), and the survival rate of the experimental group is higher than that of the control group (P<0.05).

TABLE-US-00003 TABLE 3 Disease Survival incidence rate Group (%) (%) Prognosis Weaned piglets Control group 10 91.6 Normal Experimental group 6.6 96.6 Excellent Care pigs Control group 8.3 95.0 Normal Experimental group 3.3 96.6 Excellent Finishing pigs Control group 3.3 96.6 Normal Experimental group 0 98.3 Excellent

Embodiment 4 Use of Taurine in Treatment of the Porcine Epidemic Diarrhea of Weaned Piglets, Care Pigs and Finishing Pigs

[0047] Treatment of the porcine epidemic diarrhea on the weaned piglets, the care pigs and the finishing pigs with taurine was implemented by orally administering taurine to the pigs, wherein the administration may be carried out by means of feeding in water or mixed feeding.

[0048] Drug Administration Time:

[0049] the administration was carried out from the day of occurrence of the disease, and in consideration of the use-cost, the drug administration time is preferably 3-30 days, and more preferably 7-14 days. The effect is subject to an obvious time-effect relationship.

[0050] Drug Administration Dosage:

[0051] 0.1-2% by weight of taurine was added in the daily-drinking water for the pigs to drink freely; or taurine accounting for 0.2-5% of the feed was added thereto, which is equivalent to a dosage of 100-10000 mg per kilogram of body weight per day of taurine, and the administration was in a single dose or in divided doses. The effect is subject to an obvious quantity-effect relationship.

[0052] Specific Operations:

[0053] 60 diseased weaned piglets, 60 diseased care pigs and 60 diseased finishing pigs were selected, and were randomly divided into two groups equivalently. Control group: conventional supportive therapy (fluid infusion+antibiotic therapy+atropine sulfate); experimental group: treatment with taurine (the dosage of taurine was 300 mg per kilogram of body weight per day). The treatment results of the two groups are listed in Table 4. As seen from Table 4, the survival rate of the experimental group is higher than that of the control group (P<0.05).

TABLE-US-00004 TABLE 4 Group Survival rate (%) Prognosis Weaned piglets Control group 86.6 General Experimental group 90.0 Good Care pigs Control group 90.0 General Experimental group 93.3 Good Finishing pigs Control group 96.6 General Experimental group 100 Good

Embodiment 5

[0054] According to methods as described in Embodiment 2 and Embodiment 4, treatment effects of taurine on porcine transmissible gastroenteritis, rotavirus diarrhea and pseudorabies viral diarrhea of the newborn piglets, the weaned piglets, the care pigs and the finishing pigs were tested. The results are shown in Table 5. The dosage of taurine for the newborn piglets was the same as that in Embodiment 2; and the dosage of taurine for the weaned piglets, the care pigs and the finishing pigs was the same as that in Embodiment 4. As seen from Table 5, taurine can be used for treatment of the porcine transmissible gastroenteritis and the rotavirus diarrhea, but the treatment effects of taurine on the porcine transmissible gastroenteritis and the rotavirus diarrhea are poorer than that on the porcine epidemic diarrhea. However, taurine has no treatment effect on the pseudorabies viral diarrhea, for following reasons: in one aspect, a pseudorabies virus which belongs to a virus of genus porcine herpesvirus of family herpesviridae, is a virus having relatively strong resistibility among the family herpesviridae and still has infectivity after being treated with 0.5% phenol for 32 days; in another aspect, the category of the virus may be also a factor causing failure of the treatment effect. The porcine pseudorabies virus is a DNA virus, whereas the porcine epidemic diarrhea virus, the porcine transmissible gastroenteritis virus and the rotavirus all belong to RNA viruses.

TABLE-US-00005 TABLE 5 Survival rate Group (%) Prognosis Transmissible Newborn piglets Control group 9.8 Poor gastroenteritis Experimental group 16.6 Good Weaned piglets Control group 83.3 Poor Experimental group 90 Good Care pigs Control group 90 Poor Experimental group 93.3 Good Finishing pigs Control group 96.6 Poor Experimental group 96.6 Good Rotavirus diarrhea Newborn piglets Control group 88.7 Poor Experimental group 93.6 Good Weaned piglets Control group 90 General Experimental group 96.6 Good Care pigs Control group 93.3 General Experimental group 96.6 Good Pseudorabies viral Newborn piglets Control group 0 — diarrhea Experimental group 0 — Care pigs Control group 46.6 General Experimental group 43.3 General

Embodiment 6

[0055] A pharmaceutical composition comprises following components by weight percent: 85% of taurine, 10% of a vitamin complex, and 5% of a flavoring agent.

[0056] The vitamin complex consists of vitamin A, vitamin B.sub.1, vitamin B.sub.2, vitamin B.sub.6, vitamin B.sub.12, vitamin C, vitamin D.sub.3, vitamin E, vitamin K.sub.3, biotin, niacin, calcium pantothenate, folic acid and inose.

[0057] The flavoring agent consists of vanillin, aspartame and chili powder.

Embodiment 7

[0058] A pharmaceutical composition comprises the following components by weight percent: 5% of taurine, 85% of the vitamin complex, and 10% of the flavoring agent.

[0059] The vitamin complex consists of vitamin A, vitamin B.sub.1, vitamin B.sub.2, vitamin B.sub.6, vitamin B.sub.12, vitamin C, 25-hydroxyl-vitamin D.sub.3, vitamin E, vitamin K.sub.3, niacinamide, pantothenic acid, folic acid and glucose.

[0060] The flavoring agent consists of ethyl vanillin, acesulfame potassium and perilla seed powder.

Embodiment 8

[0061] A pharmaceutical composition comprises the following components by weight percent: 70% of taurine, 25% of the vitamin complex, and 5% of the flavoring agent.

[0062] The vitamin complex consists of vitamin A, vitamin B.sub.12, vitamin C, 25-hydroxyl-vitamin D.sub.3, vitamin E, vitamin K.sub.3, niacinamide, pantothenic acid, folic acid, inose and lactose.

[0063] The flavoring agent consists of citrus essence, sucralose and evodia powder.

Embodiment 9

[0064] A pharmaceutical composition comprises the following components by weight percent: 45% of taurine, 45% of the vitamin complex, and 10% of the flavoring agent.

[0065] The vitamin complex consists of vitamin A, vitamin C, vitamin D.sub.3, vitamin E, vitamin K.sub.3, biotin, niacinamide, pantothenic acid, folic acid, soluble starch and sucrose.

[0066] The flavoring agent consists of strawberry essence, sodium saccharin and mint powder.

Embodiment 10

[0067] A pharmaceutical composition comprises the following components by weight percent: 20% of taurine, 70% of the vitamin complex, and 10% of the flavoring agent.

[0068] The vitamin complex consists of vitamin B.sub.1, vitamin B.sub.2, vitamin B.sub.6, vitamin B.sub.12, vitamin C, vitamin E, vitamin K.sub.3, niacinamide, pantothenic acid, folic acid, starch, lactose, sucrose and glucose.

[0069] The flavoring agent consists of cream essence, xylitol, glucose and pepper.

Embodiment 11

[0070] I. The pharmaceutical composition according to Embodiment 6 was used for the prevention of porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs. Particularly, a mode of the administration for the newborn piglets was the same as the method in Embodiment 1, i.e. each pregnant sow was administered with 50 g of the pharmaceutical composition in Embodiment 6 per day, and the administration was in a single dose or in divided doses. A mode of the administration for the weaned piglets, care pigs and finishing pigs was the same as the method in Embodiment 3, i.e. a dosage of 250 mg per kilogram of body weight per day of the pharmaceutical composition in Embodiment 6, and the administration was in a single dose or in divided doses.

[0071] The prevention results of the pharmaceutical composition according to Embodiment 6 for the porcine epidemic diarrhea of newborn piglets, weaned piglets, care pigs and finishing pigs are shown in Tables 6 and 7.

TABLE-US-00006 TABLE 6 Prevention results of the newborn piglets Dosage of the Disease incidence pharmaceutical of the Death rate of composition newborn the newborn Group for the sows piglets (%) piglets (%) Control group 0 100%  100% Experimental 50 g per sow per day 83% 73.9% group

TABLE-US-00007 TABLE 7 Prevention results of the weaned piglets, care pigs and finishing pigs Disease incidence Survival Group (%) rate (%) Prognosis Weaned piglets Control group 13.3 88.3 Normal Experimental group 8.3 91.6 Excellent Care pigs Control group 11.6 93.3 Normal Experimental group 6.6 96.6 Excellent Finishing pigs Control group 3.3 96.6 Normal Experimental group 0 98.3 Excellent

[0072] II. The pharmaceutical composition according to Embodiment 6 was used for the treatment of porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs. A mode of the administration for the newborn piglets was the same as the method in Embodiment 2, i.e. the administration by drenching and/or mixed-feeding was carried out on the day when the disease occurred in the suckling piglets. The administration by drenching: a solution with a mass concentration of 5% was prepared from the pharmaceutical composition in Embodiment 6 with a dosage of 2-4 mL per time and it was taken 2-6 times per day. The administration by mixed-feeding: 4 g/L of the solution was drunk freely. For lactating sows: each sow was administered with 100 g of the pharmaceutical composition in Embodiment 6 per day and the administration was in a single dose or in divided doses. A mode of the administration for the weaned piglets, care pigs and finishing pigs was the same as the method in Embodiment 4, i.e. a dosage of 500 mg per kilogram of body weight per day of the pharmaceutical composition in Embodiment 6, and the administration was in a single dose or in divided doses.

[0073] The treatment results of the pharmaceutical composition according to Embodiment 6 for the porcine epidemic diarrhea of newborn piglets, weaned piglets, care pigs and finishing pigs are shown in Tables 8 and 9.

TABLE-US-00008 TABLE 8 Treatment results of the newborn piglets Dosage of the Dosage of the composition for pharmaceutical 10-day-aged Weaned the lactating composition for survival rate survival rate Group sows the piglets (%) (%) Prognosis Control group 0 0 7.7 2.9 Poor Experimental 100 g per sow 0.2 g per piglet 23.3 22.6 Good group per day per day

TABLE-US-00009 TABLE 9 Treatment results of the weaned piglets, care pigs and finishing pigs Group Survival rate (%) Prognosis Weaned piglets Control group 86.6 General Experimental group 93.3 Excellent Care pigs Control group 90.0 General Experimental group 96.6 Excellent Finishing pigs Control group 96.6 General Experimental group 100 Excellent

[0074] III. The treatment effects of the pharmaceutical composition in Embodiment 6 on the porcine transmissible gastroenteritis and the porcine rotavirus diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs were tested according to the method in the second step in the present embodiment. A dosage of the pharmaceutical composition for the newborn piglets was: 120 g per lactating sow per day, and 0.2 g per piglet per day. A dosage of the pharmaceutical composition for the weaned piglets, care pigs and finishing pigs was 350 mg per kilogram of body weight. The results are shown in Table 10.

TABLE-US-00010 TABLE 10 Survival rate Group (%) Prognosis Transmissible Newborn piglets Control group 11.8 Poor gastroenteritis Experimental group 18.2 Excellent Weaned piglets Control group 83.3 Poor Experimental group 86.6 Excellent Care pigs Control group 90 Poor Experimental group 93.3 Excellent Finishing pigs Control group 93.3 Poor Experimental group 96.6 Excellent Rotavirus diarrhea Newborn piglets Control group 90.5 Poor Experimental group 93.6 Excellent Weaned piglets Control group 90 General Experimental group 93.3 Excellent Care pigs Control group 93.3 General Experimental group 96.6 Excellent

Embodiment 12

[0075] I. The pharmaceutical composition in Embodiment 7 was used for the prevention of porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs. An administration method was the same as the method in Embodiment 11, and 2000 mg per kilogram of body weight of the pharmaceutical composition in Embodiment 7 was administered to the weaned piglets, care pigs and finishing pigs. The prevention results of the composition according to Embodiment 7 for the porcine epidemic diarrhea of newborn piglets, weaned piglets, care pigs and finishing pigs are shown in Tables 11 and 12.

TABLE-US-00011 TABLE 11 Prevention results of the newborn piglets Dosage of the pharmaceutical Disease incidence of the Death rate of the newborn Group composition for the sows newborn piglets (%) piglets (%) Control group 0  100% 98.3% Experimental group 400 g per sow per day 92.2% 85.1%

TABLE-US-00012 TABLE 12 Prevention results of the weaned piglets, care pigs and grow-finishing pigs Disease incidence Survival Group (%) rate (%) Prognosis Weaned piglets Control group 10.0 88.3 Normal Experimental group 8.3 91.6 Excellent Care pigs Control group 8.3 93.3 Normal Experimental group 6.6 96.6 Excellent Finishing pigs Control group 3.3 96.6 Normal Experimental group 0 98.3 Excellent

[0076] II. The pharmaceutical composition in Embodiment 7 was used for the treatment of porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs. The administration method was the same as the method in Embodiment 11, and 5000 mg per kilogram of body weight of the pharmaceutical composition in Embodiment 7 was administered to the weaned piglets, care pigs and finishing pigs. The treatment results of the composition according to Embodiment 7 for the porcine epidemic diarrhea of newborn piglets, weaned piglets, care pigs and finishing pigs are shown in Tables 13 and 14.

TABLE-US-00013 TABLE 13 Treatment results of the newborn piglets Dosage of the composition for Dosage of the 10-day-aged Weaned the lactating composition for survival rate survival rate Group sows the piglets (%) (%) Prognosis Control group 0 0 8.9 3.3 Poor Experimental 400 g per sow 1 g per piglet per 12.7 12.3 Excellent group per day day

TABLE-US-00014 TABLE 14 Treatment results of the weaned piglets, care pigs and finishing pigs Group Survival rate (%) Prognosis Weaned piglets Control group 90.0 General Experimental group 93.3 Excellent Care pigs Control group 93.3 General Experimental group 96.6 Excellent Finishing pigs Control group 96.6 General Experimental group 100 Excellent

[0077] III. The treatment effects of the pharmaceutical composition in Embodiment 7 on the porcine transmissible gastroenteritis and the porcine rotavirus diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs were tested according to the steps in Embodiment 11. A dosage of the pharmaceutical composition for the newborn piglets was: 2000 g per lactating sow per day, and 4 g per piglet per day. A dosage of the composition for the weaned piglets, care pigs and finishing pigs was 5000 mg per kilogram of body weight. The results are shown in Table 15.

TABLE-US-00015 TABLE 15 Survival rate Group (%) Prognosis Transmissible Newborn piglets Control group 6.8 Poor gastroenteritis Experimental group 13.2 Excellent Weaned piglets Control group 83.3 Poor Experimental group 90.0 Excellent Care pigs Control group 86.6 Poor Experimental group 93.3 Excellent Finishing pigs Control group 96.6 Poor Experimental group 96.6 Excellent Rotavirus diarrhea Newborn piglets Control group 91.2 Poor Experimental group 92.8 Excellent Weaned piglets Control group 90 General Experimental group 93.3 Excellent Care pigs Control group 86.6 General Experimental group 93.3 Excellent

Embodiment 13

[0078] I. The pharmaceutical composition in Embodiment 9 was used for the prevention of porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs. The administration method was the same as the method in Embodiment 11, and 450 mg per kilogram of body weight of the pharmaceutical composition in Embodiment 9 was administered to the weaned piglets, care pigs and finishing pigs. The prevention results of the composition in Embodiment 9 on the porcine epidemic diarrhea of newborn piglets, weaned piglets, care pigs and finishing pigs are shown in Tables 16 and 17.

TABLE-US-00016 TABLE 16 Prevention results of the newborn piglets Dosage of the pharmaceutical composition for the Disease incidence of the Death rate of the newborn Group sows newborn piglets (%) piglets (%) Control group 0 90.6% 96.9% Experimental 300 g per sow per day 70.9% 71.2% group

TABLE-US-00017 TABLE 17 Prevention results of the weaned piglets, care pigs and finishing pigs Disease incidence Survival Group (%) rate (%) Prognosis Weaned piglets Control group 11.6 88.3 General Experimental group 8.3 93.3 Excellent Care pigs Control group 10.0 93.3 General Experimental group 6.6 96.6 Excellent Finishing pigs Control group 3.3 96.6 Normal Experimental group 0 98.3 Excellent

[0079] II. The pharmaceutical composition in Embodiment 9 was used for the treatment of porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs. The administration method was the same as the method in Embodiment 11, and 800 mg per kilogram of body weight of the pharmaceutical composition in Embodiment 9 was administered to the weaned piglets, care pigs and finishing pigs. The treatment results of the composition in Embodiment 9 for the porcine epidemic diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs are as shown in Tables 18 and 19.

TABLE-US-00018 TABLE 18 Treatment results of the newborn piglets Dosage of the composition for Dosage of the 10-day-aged Weaned the lactating composition for survival rate survival rate Group sows the piglets (%) (%) Prognosis Control group 0 0 6.3 4.5 Poor Experimental 500 g per sow 0.8 g per piglet 27.7 26.3 Excellent group per day per day

TABLE-US-00019 TABLE 19 Treatment results of the weaned piglets, care pigs and finishing pigs Group Survival rate (%) Prognosis Weaned piglets Control group 90.0 General Experimental group 96.6 Excellent Care pigs Control group 93.3 General Experimental group 96.6 Excellent Finishing pigs Control group 96.6 General Experimental group 100 Excellent

[0080] III. The treatment effects of the pharmaceutical composition in Embodiment 9 on the porcine transmissible gastroenteritis and the rotavirus diarrhea of the newborn piglets, weaned piglets, care pigs and finishing pigs were tested according to the steps in Embodiment 11. A dosage of the composition for the newborn piglets was: 200 g per lactating sow per day, and 0.4 g per piglet per day. A dosage of the composition for the weaned piglets, care pigs and finishing pigs was 500 mg per kilogram of body weight. The results are shown in Table 20.

TABLE-US-00020 TABLE 20 Survival rate Group (%) Prognosis Transmissible Newborn piglets Control group 10.5 Poor gastroenteritis Experimental group 14.8 Excellent Weaned piglets Control group 83.3 Poor Experimental group 93.3 Excellent Care pigs Control group 86.6 Poor Experimental group 93.3 Excellent Finishing pigs Control group 96.6 Poor Experimental group 100 Excellent Rotavirus diarrhea Newborn piglets Control group 90.3 Poor Experimental group 93.9 Excellent Weaned piglets Control group 93.3 General Experimental group 93.3 Excellent Care pigs Control group 86.6 General Experimental group 93.3 Excellent